APA (7th ed.) Citation

JH, E., R, K., G, W., S, T., RI, L., K, S., . . . C, B. (2022). Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years. Pediatric blood & cancer, 69(8), e29716. https://doi.org/10.1002/pbc.29716

Chicago Style (17th ed.) Citation

JH, Estepp, et al. "Safety and Efficacy of Voxelotor in Pediatric Patients with Sickle Cell Disease Aged 4 to 11 years." Pediatric Blood & Cancer 69, no. 8 (2022): e29716. https://doi.org/10.1002/pbc.29716.

MLA (9th ed.) Citation

JH, Estepp, et al. "Safety and Efficacy of Voxelotor in Pediatric Patients with Sickle Cell Disease Aged 4 to 11 years." Pediatric Blood & Cancer, vol. 69, no. 8, 2022, p. e29716, https://doi.org/10.1002/pbc.29716.